Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jaci.2021.04.002 http://scihub22266oqcxt.onion/10.1016/j.jaci.2021.04.002 33857566!8056854!33857566     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Allergy+Clin+Immunol 2021 ; 147 (6): 2075-2082.e2 Nephropedia Template TP {{tp|p=33857566|t=2021. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines |pdf=|usr=}}{{33857566}} gab.com Text Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines JO: J Allergy Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33857566 #FOAvip Anaphylaxis to vaccines is historically a rare event. The coronavirus disease 2019 pandemic drove the need for rapid vaccine production applying a novel antigen delivery system: messenger RNA vaccines packaged in lipid nanoparticles. Unexpectedly, public vaccine administration led to a small number of severe allergic reactions, with resultant substantial public concern, especially within atopic individuals. We reviewed the constituents of the messenger RNA lipid nanoparticle vaccine and considered several contributors to these reactions: (1) contact system activation by nucleic acid, (2) complement recognition of the vaccine-activating allergic effector cells, (3) preexisting antibody recognition of polyethylene glycol, a lipid nanoparticle surface hydrophilic polymer, and (4) direct mast cell activation, coupled with potential genetic or environmental predispositions to hypersensitivity. Unfortunately, measurement of anti-polyethylene glycol antibodies in vitro is not clinically available, and the predictive value of skin testing to polyethylene glycol components as a coronavirus disease 2019 messenger RNA vaccine-specific anaphylaxis marker is unknown. Even less is known regarding the applicability of vaccine use for testing (in vitro/vivo) to ascertain pathogenesis or predict reactivity risk. Expedient and thorough research-based evaluation of patients who have suffered anaphylactic vaccine reactions and prospective clinical trials in putative at-risk individuals are needed to address these concerns during a public health crisis. Twit Text FOAVip Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines ????J Allergy Clin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33857566 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33857566 #FOAvip English Wikipedia <ref>{{Cite pmid|33857566}}</ref> Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines #MMPMID33857566 Risma KA; Edwards KM; Hummell DS; Little FF; Norton AE; Stallings A; Wood RA; Milner JD J Allergy Clin Immunol 2021[Jun]; 147 (6): 2075-2082.e2 PMID33857566show ga Anaphylaxis to vaccines is historically a rare event. The coronavirus disease 2019 pandemic drove the need for rapid vaccine production applying a novel antigen delivery system: messenger RNA vaccines packaged in lipid nanoparticles. Unexpectedly, public vaccine administration led to a small number of severe allergic reactions, with resultant substantial public concern, especially within atopic individuals. We reviewed the constituents of the messenger RNA lipid nanoparticle vaccine and considered several contributors to these reactions: (1) contact system activation by nucleic acid, (2) complement recognition of the vaccine-activating allergic effector cells, (3) preexisting antibody recognition of polyethylene glycol, a lipid nanoparticle surface hydrophilic polymer, and (4) direct mast cell activation, coupled with potential genetic or environmental predispositions to hypersensitivity. Unfortunately, measurement of anti-polyethylene glycol antibodies in vitro is not clinically available, and the predictive value of skin testing to polyethylene glycol components as a coronavirus disease 2019 messenger RNA vaccine-specific anaphylaxis marker is unknown. Even less is known regarding the applicability of vaccine use for testing (in vitro/vivo) to ascertain pathogenesis or predict reactivity risk. Expedient and thorough research-based evaluation of patients who have suffered anaphylactic vaccine reactions and prospective clinical trials in putative at-risk individuals are needed to address these concerns during a public health crisis. |2019-nCoV Vaccine mRNA-1273[MESH] |Anaphylaxis/chemically induced/*immunology[MESH] |Animals[MESH] |COVID-19 Vaccines/*adverse effects/immunology/therapeutic use[MESH] |COVID-19/*immunology/prevention & control[MESH] |Drug Hypersensitivity/*immunology/pathology[MESH] |Humans[MESH] |Lipids/*adverse effects/immunology/therapeutic use[MESH] |Mast Cells/immunology/pathology[MESH] |Nanoparticles/*adverse effects/therapeutic use[MESH] |RNA, Messenger/*adverse effects/immunology/therapeutic use[MESH] |Risk Factors[MESH]Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines (epmc).pdf DeepDyve Pubget Overpricing